Kolon TissueGene, Inc.
Founded in 1999 and listed on KOSDAQ in 2017, Kolon TissueGene is developing the osteoarthritis cell and gene therapy TG-C, now in US Phase 3 trials.
As of 2026-10-10, Kolon TissueGene, Inc. has 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- TG-CCell and gene therapy for osteoarthritis
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 2 · Not yet recruiting · 2027-10 · NCT05276011
Phase 1 · Not yet recruiting · 2027-01 · NCT06144970
Phase 3 · Completed · 2021-12 · NCT03291470
Phase 3 · Active not recruiting · 2018-10 · NCT03203330
Phase 2 · Completed · 2011-05 · NCT01221441
Phase 1 · Completed · 2007-01 · NCT00599248
R&D and key agreements
Source: DART corporate disclosureTG-C 무릎골관절염(Knee OA) · 무릎골관절염 · 미국 FDA 임상3상(2개 Pivotal study, 2024년 7월 1,066명 환자등록 완료, 추적관찰중) · Dosing began in 2018 but was voluntarily paused in 2019 over a possible cell-origin error, leading to an FDA Clinical Hold; the company received a Remove Clinical Hold Letter in 2020 and resumed dosing in December 2021. It plans to file for FDA approval (BLA) after the follow-up period ends.
TG-C 고관절골관절염(Hip OA) · 고관절골관절염 · FDA 임상2상 승인 · Received FDA approval for a Phase 2 trial, though the company plans to prioritize the more advanced knee osteoarthritis program.
TG-C 퇴행성척추디스크질환(DDD) · 퇴행성 척추 디스크질환 · 전임상 완료, FDA IND 승인(2023년 12월) · Preclinical animal studies showed a significant reduction in pain from damaged discs after TG-C injection; based on this data, the company submitted an IND to the FDA and received approval in December 2023.
Key disclosures
KRX KIND via OpenDARTShow 29 more events
Publications
PubMed · affiliation-matched- Over-Production of Therapeutic Growth Factors for Articular Cartilage Regeneration by Protein Production Platforms and Protein Packaging Cell Lines.
Biology · 2020-10 · Mobasheri A, Choi H, Martín-Vasallo P
Patents
KIPRIS · applicant-matchedUS · Published · 2026-02 · Application 19545383
US · Published · 2024-09 · Application 18900011
US · Published · 2024-09 · Application 18900083
US · Published · 2023-04 · Application 18134383
US · Published · 2023-04 · Application 18134401
US · Published · 2023-02 · Application 18108849
US · Published · 2021-12 · Application 17543911
CN · Published · 2021-12 · Application 202180092798.5
US · Published · 2021-12 · Application 18040000
EP · Published · 2021-12 · Application 21901611.0
Show 36 more patents
PCT · Published · 2021-12 · Application PCT/US2021/062042
US · Published · 2021-10 · Application 17500832
US · Published · 2021-09 · Application 17488785
US · Published · 2021-09 · Application 17488779
US · Published · 2021-02 · Application 17186332
US · Published · 2020-11 · Application 17092712
US · Published · 2020-11 · Application 17092779
CN · Published · 2020-03 · Application 202080037395.6
CN · Published · 2020-03 · Application 202080039865.2
CN · Published · 2020-03 · Application 202080039370.X
US · Published · 2020-03 · Application 17599829
US · Published · 2020-03 · Application 17599826
US · Registered · 2020-03 · Application 17599831
EP · Published · 2020-03 · Application 20783688.3
EP · Published · 2020-03 · Application 20785357.3
EP · Registered · 2020-03 · Application 20784818.5
PCT · Published · 2020-03 · Application PCT/US2020/025684
PCT · Published · 2020-03 · Application PCT/US2020/025705
PCT · Published · 2020-03 · Application PCT/US2020/025689
US · Published · 2020-03 · Application 16810667
US · Published · 2019-03 · Application 16370385
US · Published · 2019-03 · Application 16370456
CN · Published · 2018-06 · Application 201880055974.6
CN · Published · 2018-06 · Application 201880055969.5
US · Registered · 2018-06 · Application 16627528
US · Registered · 2018-06 · Application 16627541
EP · Published · 2018-06 · Application 26174992.3
EP · Published · 2018-06 · Application 18824811.6
EP · Published · 2018-06 · Application 26163454.7
EP · Registered · 2018-06 · Application 18823401.7
PCT · Published · 2018-06 · Application PCT/KR2018/007437
PCT · Published · 2018-06 · Application PCT/KR2018/007438
EP · Registered · 2016-02 · Application 16746880.0
EP · Registered · 2014-11 · Application 14858772.8
EP · Published · 2009-03 · Application 22167719.8
EP · Registered · 2009-03 · Application 17001734.7
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot66
- PerplexityPerplexityBot3
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Kolon TissueGene, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition